WO1998050383A1 - Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 - Google Patents
Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 Download PDFInfo
- Publication number
- WO1998050383A1 WO1998050383A1 PCT/FR1998/000886 FR9800886W WO9850383A1 WO 1998050383 A1 WO1998050383 A1 WO 1998050383A1 FR 9800886 W FR9800886 W FR 9800886W WO 9850383 A1 WO9850383 A1 WO 9850383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- chloro
- dihydro
- compound
- oxadiazol
- Prior art date
Links
- 0 Cc(c(*)c1)c(*)c(O)c1C(O1)=**(*)C1=O Chemical compound Cc(c(*)c1)c(*)c(O)c1C(O1)=**(*)C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Definitions
- R ⁇ represents a hydrogen atom or a (C 1 -C 4 ) alkyl or (C 3 -C 7 ) cycloalkylmethyl group
- X x represents a hydrogen atom or a (C 1 -C 4 ) - alkoxy group
- OR x and X- L together represent a group of formula -OCH 2 0-, -0 (CH 2 ) 2 -, -0 (CH 2 ) 3 -, -0 (CH 2 ) 2 0- or -0 (CH 2) 3 0-,
- X 2 represents a hydrogen atom, an amino group or a group of general formula -NHC0 2 R wherein R is (C 1 -C 4) alkyl or phenyl (C 1 -C 2 ) alkyl, X 3 represents a hydrogen or halogen atom, n represents the number 0, 1, 2 or 3, and
- Het represents either a pyrrolidin-1-yl group or a piperidin-1-yl group optionally substituted in position 4 by a hydroxy, amino, diethylamino, acetylamino, methylsulfonylamino, carbamoyl, phenyl, phenylmethyl or 1H-imidazol-4- group yle, either an 1H-hexahydroazepin-1-yle group, or an 8-azabicyclo [3.2.1] oct-8-yle group, or a 4- (phenylmethyl) piperazin-1-yl group, or a 4-methyl group - hexahydro-1, 4-diazepin-l-yle, or a group 1, 2, 3, 4-tetra-hydroisoquinoline-2 -yle, or a group 1-azabicyclo [2.2.2] - oct-3-yle general formula
- Y represents a hydrogen atom or a (- L -Cg) alkyl or phenyl (C 1 -C 4 ) alkyl group
- Z represents a chlorine, bromine or iodine atom, or a methylsulfonyl or 4-methylphenylsulfonyl group.
- the compounds of the invention can exist in the form of pure enantiomers or mixtures of enantiomers.
- the compounds of the invention may exist in the form of bases or of addition salts with acids.
- X 2 represents an amino group
- the latter reacts with phosgene, and the product obtained is esterified with an alcohol of general formula ROH, in which R is defined as above, the group amino being thus protected by a group -C0 2 R.
- a compound of general formula (I) in which Het represents a substituted or unsubstituted piperidin-1-yl group can, of course, be transformed according to any known method into another compound of general formula (I), in which Het represents a group piperidin-1-yl substituted differently.
- Het represents a 1-azabicyclo [2.2.2] - oct-3-yl group
- the starting alcohols of general formula HO- (CH 2 ) n -Het are commercially available or can be prepared according to any known method, for example those described in Synthetic Communications (1992) 22 (13) 1895-1911 and in Khim . Geterosikl. Soedin. (1992) 11 1509-1512.
- the mixture is cooled using an ice bath, the precipitate is collected by filtration, rinsed with ethanol and dried under reduced pressure at 80 ° C for 2 h 30 min.
- the mixture is concentrated under reduced pressure, the residue is taken up in water, the solution is washed three times with chloroform, an aqueous ammonia solution is added and extraction is carried out with chloroform.
- the organic phase is dried, the solvent is evaporated off under reduced pressure, and the residue is triturated in acetone.
- the mixture is diluted with water, it is extracted with ethyl acetate and, after usual treatment of the organic phase, 42 g of compound are obtained which is recrystallized from a mixture of diethyl ether and diisopropyl ether. Melting point: 105-106 ° C. 5.3. Hydrazide of 8-amino-7-chloro-2, 3-dehydro-l, 4-benzod ⁇ oxme-5-carboxylic acid.
- the precipitate is collected by filtration, it is rinsed with diethyl ether, it is taken up in water, the aqueous solution is washed with diethyl ether, the water is evaporated under reduced pressure, the residue is triturated in ethanol, filtered and dried. 1.72 g of compound are obtained.
- Example 9 (Compound No. 1B). 5- (4-Amino-5-chloro-2-methoxyphenyl) -3- [2- (piperidin-1- yl) ethyl] -1, 3, 4-oxadiazol-2 (3H) -one.
- the mixture is diluted with water, it is extracted with ethyl acetate and, after usual treatment of the organic phase, 42 g of compound are obtained which is recrystallized from a mixture of diethyl ether and diisopropyl ether. Melting point: 105-106 ° C.
- Phenylmethyl carbamate [4- [4- (2-Bromoethyl) -5-oxo-4, 5-dihydro-1,3,4-oxadiazol-2-yl] -2-chloro-5-methoxyphenyl] carbamate.
- Table A which follows illustrates the chemical structures and the physical properties of some compounds of general formula (I) in which Het represents a 1-aza-bicyclo [2.2.2] oct-3-yl group. In the columns “Y” and “Z”, “-” denotes a compound in the basic state. Table A
- the compounds of the invention have been the subject of tests which have demonstrated their interest as substances with therapeutic activities.
- the compounds of the invention were studied as to their affinity for 5-HT 4 receptors in the guinea pig striatum according to the method described by Grossman et al. in Br. J. Pharmacol. (1993) 109 618-624.
- Guinea pigs (Hartley, Charles River, France) weighing 300 to 400 g are euthanized, the brains are removed, the striata are excised and frozen at -80 ° C.
- the IC 50 values of the most active compounds are of the order of 5 nM.
- the compounds of the invention have also been studied as to their agonist or antagonist effects with respect to 5-HT 4 receptors in the rat esophagus according to the method described by Baxter et al. in Naunyn Schmied. Arch. Phar acol. (1991) 343,439.
- the preparation is exposed to serotonin (1 ⁇ M) in order to quantify the maximum relaxation.
- the tissue is washed and, after a period of 20 min, 0.5 ⁇ M of carbachol is again added, and the preparation is exposed to the compound to be studied, in increasing cumulative concentrations of 0.1 to 1 ⁇ M.
- Compounds that induce relaxation are characterized as 5-HT 4 agonists.
- the preparation is exposed to serotonin in increasing cumulative concentrations, from 0.1 nM up to a concentration inducing maximum relaxation, and the relaxation curve due to serotonin, in the presence of the compound to be studied, is then compared to a control curve established in the absence of said compound. If its presence induces a shift of the curve to the right, the compound studied is characterized as a 5-HT 4 antagonist.
- results of the biological tests carried out on the compounds of the invention show that they are ligands for serotonergic receptors of the 5-HT 4 types, and that they act as agonists or antagonists.
- the compounds can therefore be used for the treatment and prevention of disorders in which the 5-HT 4 receptors are involved, whether in the central nervous system, the gastrointestinal system, the cardiovascular system or the urinary system.
- these disorders and disorders include in particular neurological and psychiatric disorders such as cognitive disorders, psychoses, compulsive and obsessive behaviors and states of depression and anxiety.
- Cognitive impairment includes, for example, memory and attention deficits, dementia (senile dementia such as Alzheimer's or age-related dementia), cerebrovascular impairment, Parkinson's disease .
- Psychoses include, for example, paranoia, schizophrenia, mania and autism.
- Compulsive and obsessive behaviors include, for example, eating disorders such as binge eating or loss of appetite.
- Depression and anxiety states include, for example, anticipatory type anxiety (before surgery, before dental treatment, etc.), anxiety caused by dependence or withdrawal from alcohol, drugs, mania, seasonal affective disorders, migraines, nausea.
- these disorders and disorders include in particular vomiting induced by medical treatment, direct or indirect disorders of the gastromotility of the esophagus, stomach or intestines, specific diseases such as dyspepsia, ulcer, gastroesophageal reflux, flatulence, irritable bowel syndrome, disorders of intestinal secretion, diarrhea, for example those induced by cholera or carcinoid syndrome.
- these disorders and disorders include in particular pathologies linked, directly or indirectly, to cardiac arrhythmias.
- these disorders and disorders include in particular incontinence of all kinds, as well as their causes or consequences, for example infections, stones or kidney damage.
- the compounds of the invention can be presented in any form of composition suitable for enteral or parenteral administration, such as tablets, dragees, capsules, capsules, suspensions or oral or injectable solutions such as syrups or ampoules, transdermal patches, suppositories, etc, combined with suitable excipients, and dosed to allow daily administration of 0.005 to 20 mg / kg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54777898A JP2002504896A (ja) | 1997-05-06 | 1998-05-04 | 5−フェニル−1,3,4−オキサジアゾール−2(3h)−オン誘導体およびそれらの5−ht4リガンドとしての使用 |
EP98924364A EP0980370A1 (fr) | 1997-05-06 | 1998-05-04 | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 |
AU76587/98A AU7658798A (en) | 1997-05-06 | 1998-05-04 | 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9705537A FR2763067B1 (fr) | 1997-05-06 | 1997-05-06 | Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
FR97/05537 | 1997-05-06 | ||
FR9705538A FR2763069B1 (fr) | 1997-05-06 | 1997-05-06 | Derives de 1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
FR97/05538 | 1997-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998050383A1 true WO1998050383A1 (fr) | 1998-11-12 |
WO1998050383A8 WO1998050383A8 (fr) | 1999-04-22 |
Family
ID=26233510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/000886 WO1998050383A1 (fr) | 1997-05-06 | 1998-05-04 | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0980370A1 (fr) |
JP (1) | JP2002504896A (fr) |
AU (1) | AU7658798A (fr) |
WO (1) | WO1998050383A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014152132A1 (fr) * | 2013-03-15 | 2014-09-25 | Monsanto Technology Llc | Azoles n,c-disubstitués et compositions et procédés de lutte contre les nématodes nuisibles |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0221702A2 (fr) * | 1985-10-19 | 1987-05-13 | Beecham Group Plc | Dérivés quinuclidine |
FR2719842A1 (fr) * | 1994-05-10 | 1995-11-17 | Synthelabo | Sels quaternaires de dérivés de 1-azabicyclo [2.2.2] octane, leur préparation et leur application en thérapeutique. |
WO1995032965A1 (fr) * | 1994-06-01 | 1995-12-07 | Yamanouchi Pharmaceutical Co. Ltd. | Derive de l'oxadiazole et composition medicinale a base de ce dernier |
WO1997017345A1 (fr) * | 1995-11-09 | 1997-05-15 | Synthelabo | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3? |
-
1998
- 1998-05-04 AU AU76587/98A patent/AU7658798A/en not_active Abandoned
- 1998-05-04 EP EP98924364A patent/EP0980370A1/fr not_active Withdrawn
- 1998-05-04 WO PCT/FR1998/000886 patent/WO1998050383A1/fr not_active Application Discontinuation
- 1998-05-04 JP JP54777898A patent/JP2002504896A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0221702A2 (fr) * | 1985-10-19 | 1987-05-13 | Beecham Group Plc | Dérivés quinuclidine |
FR2719842A1 (fr) * | 1994-05-10 | 1995-11-17 | Synthelabo | Sels quaternaires de dérivés de 1-azabicyclo [2.2.2] octane, leur préparation et leur application en thérapeutique. |
WO1995032965A1 (fr) * | 1994-06-01 | 1995-12-07 | Yamanouchi Pharmaceutical Co. Ltd. | Derive de l'oxadiazole et composition medicinale a base de ce dernier |
WO1997017345A1 (fr) * | 1995-11-09 | 1997-05-15 | Synthelabo | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3? |
Non-Patent Citations (1)
Title |
---|
D. YANG ET AL.: "New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists of 5-HT4 receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 14 February 1997 (1997-02-14), WASHINGTON DC, US, pages 608 - 21, XP002051774 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014152132A1 (fr) * | 2013-03-15 | 2014-09-25 | Monsanto Technology Llc | Azoles n,c-disubstitués et compositions et procédés de lutte contre les nématodes nuisibles |
US9051309B2 (en) | 2013-03-15 | 2015-06-09 | Monsanto Technology Llc | 3,5-disubstituted-1,3,4-oxadiazol-2(3H)-ones and compositions and methods for controlling nematode pests |
CN105163586A (zh) * | 2013-03-15 | 2015-12-16 | 孟山都技术公司 | 用于控制线虫害虫的n-、c-二取代的唑类 |
EA027989B1 (ru) * | 2013-03-15 | 2017-09-29 | Монсанто Текнолоджи Ллс | N-,c-дизамещенные азолы для борьбы с нематодными вредителями |
Also Published As
Publication number | Publication date |
---|---|
EP0980370A1 (fr) | 2000-02-23 |
AU7658798A (en) | 1998-11-27 |
WO1998050383A8 (fr) | 1999-04-22 |
JP2002504896A (ja) | 2002-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0863897B1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h3 | |
JP4898062B2 (ja) | アザ二環式カルバメートおよびアルファ−7ニコチン性アセチルコリンレセプターアゴニストとしてのその使用 | |
AU2001262257A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
HU221433B (en) | Oxadiazole and tiadiazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
FR2769915A1 (fr) | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique | |
SK112398A3 (en) | Oxa- and thia-diazole muscarinic receptor antagonists | |
WO1998015552A1 (fr) | DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
US5663173A (en) | N-[(1,4-diazabicyclo[2.2.2] oct-2-yl)methyl] benzamide derivatives, their preparations and their application in therapeutics | |
EP0975631B1 (fr) | Derives de 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3h)-one en tant que ligands des recepteurs 5-ht4 | |
JPH06211838A (ja) | ピペリジン誘導体、その製造法および治療への応用 | |
WO1998050383A1 (fr) | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 | |
JP2001521935A (ja) | 3−アミノアルキルアミノ−2h−1,4−ベンゾキシアジン及び3−アミノアルキルアミノ−2h−1,4−ベンゾチアジン:ドーパミン受容体サブタイプ特定の配位子 | |
EP0980368B1 (fr) | Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 | |
FR2763069A1 (fr) | Derives de 1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
JPH06157518A (ja) | 新規なオキサジアゾール誘導体又はその塩 | |
FR2763067A1 (fr) | Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
WO1998011112A1 (fr) | Derives d'indazole tricyclique, leur preparation et leur application en therapeutique | |
FR2741069A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
FR2625201A1 (fr) | Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant | |
FR2741070A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
JP2002509151A (ja) | ニューロキニンアンタゴニストとしてのピペラジノ誘導体 | |
FR2759699A1 (fr) | Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
FR2745574A1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique | |
WO1998005664A1 (fr) | DERIVES D'ACIDE 6,7,8,9-TETRAHYDRO-5H-IMIDAZO[1,2-a]AZEPINE-3-ACETIQUE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
FR2598417A1 (fr) | Esters d'azoniaspironortropanols, procede pour leur preparation et medicaments les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: FIGURE ADDED |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09403777 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998924364 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998924364 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998924364 Country of ref document: EP |